Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group
作者： Lars M. Wagner , Maryam Fouladi , Atif Ahmed , Mark D. Krailo , Brenda Weigel
DOI: 10.1002/PBC.25334
关键词: Oncology 、 Osteosarcoma 、 Internal medicine 、 Phases of clinical research 、 Cixutumumab 、 Sarcoma 、 Sirolimus 、 Rhabdomyosarcoma 、 Medicine 、 Temsirolimus 、 Soft tissue sarcoma
摘要: Background The combined inhibition of insulin-growth factor type 1 receptor (IGF-1R) and the mammalian target rapamycin (mTOR) has shown activity in preclinical models pediatric sarcoma adult patients. We evaluated anti-IGF-1R antibody cixutumumab with mTOR inhibitor temsirolimus patients relapsed or refractory Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, other soft tissue using recommended dosages from a phase I trial.
sci-hub.se 参考文章(28)
Brenda Weigel, Suman Malempati, Joel M. Reid, Stephan D. Voss, Steven Y. Cho, Helen X. Chen, Mark Krailo, Doojduen Villaluna, Peter C. Adamson, Susan M. Blaney, Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group. Pediatric Blood & Cancer. ,vol. 61, pp. 452- 456 ,(2014) , 10.1002/PBC.24605
P. Schöffski, D. Adkins, J.-Y. Blay, T. Gil, A.D. Elias, P. Rutkowski, G.K. Pennock, H. Youssoufian, H. Gelderblom, R. Willey, D.O. Grebennik, An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours European Journal of Cancer. ,vol. 49, pp. 3219- 3228 ,(2013) , 10.1016/J.EJCA.2013.06.010
Vivek Subbiah, Aung Naing, Robert E. Brown, Helen Chen, Laurence Doyle, Patricia LoRusso, Robert Benjamin, Pete Anderson, Razelle Kurzrock, Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. PLOS ONE. ,vol. 6, ,(2011) , 10.1371/JOURNAL.PONE.0018424
Aung Naing, Patricia LoRusso, Siqing Fu, David S. Hong, Pete Anderson, Robert S. Benjamin, Joseph Ludwig, Helen X. Chen, Laurence A. Doyle, Razelle Kurzrock, Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors Clinical Cancer Research. ,vol. 18, pp. 2625- 2631 ,(2012) , 10.1158/1078-0432.CCR-12-0061
Pedro J. Beltran, Young-Ah Chung, Gordon Moody, Petia Mitchell, Elaina Cajulis, Steven Vonderfecht, Richard Kendall, Robert Radinsky, Frank J. Calzone, Efficacy of Ganitumab (AMG 479), Alone and in Combination with Rapamycin, in Ewing's and Osteogenic Sarcoma Models Journal of Pharmacology and Experimental Therapeutics. ,vol. 337, pp. 644- 654 ,(2011) , 10.1124/JPET.110.178400
C Garofalo, M C Manara, G Nicoletti, M T Marino, P-L Lollini, A Astolfi, G Pandini, J A López-Guerrero, K-L Schaefer, A Belfiore, P Picci, K Scotlandi, Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene. ,vol. 30, pp. 2730- 2740 ,(2011) , 10.1038/ONC.2010.640
Cynthia X. Ma, Vera J. Suman, Matthew Goetz, Paul Haluska, Timothy Moynihan, Rita Nanda, Olufunmilayo Olopade, Timothy Pluard, Zhanfang Guo, Helen X. Chen, Charles Erlichman, Matthew J. Ellis, Gini F. Fleming, A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer Breast Cancer Research and Treatment. ,vol. 139, pp. 145- 153 ,(2013) , 10.1007/S10549-013-2528-8
E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) European Journal of Cancer. ,vol. 45, pp. 228- 247 ,(2009) , 10.1016/J.EJCA.2008.10.026
David Olmos, Ana Sofia Martins, Robin L. Jones, Salma Alam, Michelle Scurr, Ian R. Judson, Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations. Sarcoma. ,vol. 2011, pp. 402508- 402508 ,(2011) , 10.1155/2011/402508
X Wan, B Harkavy, N Shen, P Grohar, L J Helman, Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. ,vol. 26, pp. 1932- 1940 ,(2007) , 10.1038/SJ.ONC.1209990